Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in Combination With Ranibizumab in Subjects With Wet AMD

Next Previous
Trial Profile

A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in Combination With Ranibizumab in Subjects With Wet AMD

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary) ; Sozinibercept (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; First in man
  • Sponsors Opthea

Most Recent Events

  • 07 Jan 2025 According to an Opthea media release, company announced publication of data from this study in the peer-reviewed journal Translational Vision Science & Technology (TVST), issued on December 19, 2024.
  • 22 Jul 2019 According to an Opthea media release, data from this trial will be presented at the Ophthalmology Innovation Summit (OIS) in Chicago on Thursday, July 25th, 2019.
  • 14 Sep 2018 Results published in the an Opthea Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top